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Abstract
Background: To perform a systematic review and network meta-analysis (NMA) to compare the risk of serious infections
with immunosuppressive medications and glucocorticoids in lupus nephritis.
Methods: A trained librarian performed two searches: (1) PubMed for all lupus nephritis trials from the end dates for the
systematic review for the 2012 American College of Rheumatology (ACR) lupus nephritis treatment guidelines and the
2012 Cochrane Systematic Review on treatments for lupus nephritis, to September 2013; and (2) PubMed and SCOPUS
for all lupus trials (excluding lupus nephritis) from inception to February 2014, to obtain additional trials for harms data in
any lupus patient. The search was updated to May 2016. Duplicate title/abstract review and duplicate data abstractions by
two abstractors independently was performed for all eligible studies, including those studies abstracted for the 2012 ACR
lupus nephritis treatment guidelines and the 2012 Cochrane Systematic Review on lupus nephritis treatments. We
performed a systematic review and a Bayesian NMA, including randomized controlled trials (RCTs) of immunosuppressive
drugs or glucocorticoids in patients with lupus nephritis assessing serious infection risk. Markov chain Monte Carlo
methods were used to model 95 % credible intervals (CrI). Sensitivity analyses examined the robustness of estimates.
Results: A total of 32 RCTs with 2611 patients provided data. There were 26 two-arm, five three-arm, and one four-arm
trials. We found that tacrolimus was associated with significantly lower risk of serious infections compared to
glucocorticoids, cyclophosphamide (CYC), mycophenolate mofetil (MMF), and azathioprine (AZA) with odds ratios (95 %
CrI) of 0.33 (0.12–0.88), 0.37 (0.15–0.87), 0.340 (0.18–0.81), and 0.32 (0.12–0.81), respectively. Conversely, CYC low dose (LD),
CYC high dose (HD), and HD glucocorticoids were associated with higher odds of serious infections compared to
tacrolimus, ranging from 4.84 to 12.83. We also found that MMF followed by AZA (MMF-AZA) was associated with
significantly lower risk of serious infections as compared to CYC LD, CYC HD, CYC-AZA, or HD glucocorticoids with odds
ratios (95 % CrI) of 0.09 (0.01–0.76), 0.07 (0.01–0.54), 0.14 (0.02–0.71), and 0.03 (0.00–0.56), respectively. Estimates were
similar to pair-wise meta-analyses. Sensitivity analyses that varied estimate (odds ratio vs. Peto’s odds ratio), method
(random vs. fixed effects model), data (sepsis vs. serious infection data; exclusion of observational studies), treatment
grouping (CYC and CYC HD as a combined treatment group vs. separate), made little/no difference to these estimates.
Conclusions: Tacrolimus and MMF-AZA combination were associated with lower risk of serious infections compared to
other immunosuppressive drugs or glucocorticoids for lupus nephritis. In conjunction with comparative efficacy data,
these data can help patients make informed decisions about treatment options for lupus nephritis.
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Background
Lupus nephritis is successfully treated with immunosup-
pressive drugs and glucocorticoids [1]. The benefits of
these lupus treatments are well known with well-
documented improved renal survival and function as well
as reduced mortality with treatment [2–4]. A key concern
for patients with lupus is the risk of infections (including
serious infections) with immunosuppressive drugs and
glucocorticoids, since both treatments suppress the im-
mune system [5–7]. This concern likely plays a significant
role in a patient’s decision regarding whether to take these
medications, and how long to continue treatment, some-
times despite a strong physician recommendation.
Whether the risk of serious infections differs by the type
of medication in lupus nephritis is unknown and contro-
versial. A meta-analysis of treatments for lupus nephritis
showed that the risk of major infection was not higher
with cyclophosphamide (CYC) or azathioprine (AZA) plus
glucocorticoids versus glucocorticoids alone [8]. In an-
other meta-analysis, mycophenolate mofetil (MMF) was
associated with a lower risk of overall infections compared
with CYC, with a risk ratio of 0.65 [9]. On the other hand,
a more updated and comprehensive 2012 Cochrane sys-
tematic review on lupus nephritis treatments showed that
MMF was not associated with any significantly different
risk of major infections (defined as infections other than
herpes zoster) compared to intravenous CYC (the relative
risk was 1.11 (95 % confidence interval, 0.74–1.68)) [10,
11]. The findings from these meta-analyses differ due to
differences in inclusion criteria, outcome (major infection
vs. overall infection) and comparisons. Published meta-
analyses, although methodologically sound, suffer from
several limitations: (1) comparisons of most drugs were
based on a few studies in most cases, thus making them
potentially underpowered; (2) some studies included in
meta-analyses analyzed major/serious infections while
others analyzed all infections, combining these likely led
to heterogeneity within such comparisons and also differ-
ences between meta-analyses; and (3) indirect compari-
sons between medications were not performed where
head-to-head studies were not available. Lumley et al. [12]
described network meta-analysis (NMA) as a way for
indirect comparisons of treatments, where head-to-head
trials are lacking.
Our aim was to overcome these challenges and conduct
a state-of-the-art analysis. We therefore, performed a sys-
tematic review, meta-analysis and NMA of all lupus
nephritis trials to date to compare the risk of serious infec-
tions with immunosuppressive and glucocorticoid treat-
ment in lupus nephritis.
Methods
Systematic review methods
We conducted this systematic review and NMA based on
the AHRQ recommendations [13] and the Cochrane hand-
book [14], and reported it according to the PRISMA guide-
lines [15]. No Institutional Review Board approval was
needed since the study included only analyses of published
data. The study protocol was registered in PROSPERO,
CRD42016032965 (http://www.crd.york.ac.uk/PROSPERO/
display_record.asp?ID=CRD42016032965). We used the
Cochrane systematic review [10], as well as the systematic
review conducted for the American College of Rheumatol-
ogy guidelines for treatment of lupus nephritis [16], to
identify eligible studies. Searches were updated to Septem-
ber 2013 to identify additional studies using PubMed
(Additional file 1: Appendix 1A); the search was updated
to May 2016. We considered using harms data related to
medications from any lupus randomized controlled trial
(RCT), not just from lupus nephritis RCTs, by using a
search in PubMed and SCOPUS from inception to Febru-
ary 2014 (Additional file 1: Appendix 1B). Examination of
the data from this search revealed little additive data for
harms for most outcomes of interest (16 RCTs; most had
no usable data). Therefore, we determined that the advan-
tage of inclusion of these data was outweighed by the
disadvantage of increasing heterogeneity of patient popu-
lation (from lupus nephritis to lupus). We included RCTs
or controlled clinical trials for lupus nephritis that con-
tained the common immunosuppressive drugs including
CYC, MMF, AZA, cyclosporine (CSA), tacrolimus (TAC),
rituximab (RTX), or glucocorticoids as one of the compar-
ators. Belimumab studies could not be included in this
systematic review since these studies excluded patients
with active lupus nephritis and a Cochrane systematic
review of belimumab for lupus is underway [17]. There
were no restrictions with regard to dosage or duration
of intervention. We limited our search to the English
language. The PICO (Patient, Intervention, Comparator,
Outcome) were defined as follows:
P: Adults 18 years or older, meeting the 1987 American
College of Rheumatology Classification criteria for
SLE [18] with lupus nephritis.
Singh et al. BMC Medicine  (2016) 14:137 Page 2 of 12
I: Interventions were immunosuppressant alone or in
combination with other immunosuppressant or
biologics (such as RTX) or corticosteroid. Medication
doses were categorized as low, standard, or high dose.
C: Placebo or another immunosuppressant with/without
biologic, at any dose of these medications.
O: Serious infections, defined as any of the following:
serious infection, major infection, severe infection,
sepsis, or bacterial pneumonia. We refer to these as
serious infection from here onwards.
Two trained abstractors independently reviewed abstract
and title in duplicate (AO, AB) and selected articles for full
PDF download. Two independent abstractors (AO, AB)
abstracted all the data in duplicate and entered it directly
into Microsoft excel sheets, which were pre-piloted for
data abstraction. Another research associate checked the
data for accuracy (AM). Studies were abstracted for this
analysis if they included adults with lupus nephritis, one of
the immunosuppressant drugs or glucocorticoids, and re-
ported serious infection. An adjudicator (JS) resolved any
disagreements not resolved by consensus.
Two reviewers (AO, JS) assessed the risk of bias ac-
cording to the Cochrane risk of bias tool [19], examining
the domains of randomization sequence generation, allo-
cation sequence concealment, blinding of participants,
personnel and outcome assessors, incomplete outcome
data (primary outcome data reporting, dropout rates and
reasons for withdrawal, appropriate imputation of miss-
ing data, an overall completion rate ≥ 80 %), and select-
ive outcome reporting and other potential threats to
validity (considering external validity, e.g., relevant use
of co-interventions, bias due to funding source). Each
criterion was explicitly judged as follows: Yes = low risk
of bias; No = high risk of bias; Unclear = either lack of
information or uncertainty about potential for bias. We
resolved any disagreements with consensus. We planned
funnel plots to assess publication bias.
Pair-wise meta-analysis was conducted when data were
sufficiently clinically and statistically homogeneous. We
calculated the mean difference (MD) for the continuous
and relative risk (RR) or Peto odds ratio (OR) (for rare
events), for the dichotomous data. Heterogeneity of data
was assessed by using the χ2 test, with a P value < 0.10 in-
dicating significant heterogeneity, and the I2 statistic [20],
with values > 50 % indicating substantial heterogeneity.
NMA methods
We conducted Bayesian mixed treatment comparison
(MTC) meta-analyses. We used the WinBUGS software
(MRC Biostatistics Unit, Cambridge, UK) to conduct
Bayesian MTC meta-analysis using a binomial likelihood
model that allows inclusion of multi-arm trials [21, 22].
We used the random-effects network meta-analyses as a
conservative approach, since we anticipated some hetero-
geneity in study populations. We assessed the model fit
and chose the model based on the assessment of the devi-
ance information criterion (DIC) and the comparison of
residual deviance to the number of unconstrained data
points [21, 23].
We assigned vague priors, such as N(0, 1002), for basic
parameters throughout [21] and informative priors for
the variance parameter based on Turner et al. [24]. To
ensure convergence was reached, trace plots and the
Brooks-Gelman-Rubin statistic were assessed [25]. Three
chains were fit in WinBUGS for each analysis, with 40,000
iterations, and a burn-in of 40,000 iterations [25, 26]. We
calculated point estimates and 95 % credible intervals (CrI)
for OR using the Markov Chain Monte Carlo methods. In
order to check the consistency of the NMA results, we
conducted the inconsistency analysis and constructed an
inconsistency plot, and compared these results with our
NMA results based on consistency model [27]. Heterogen-
eity of data was assessed by using the Tau-squared test,
which examines heterogeneity due to study and study–
drug interaction (smaller values indicate a better model).
There is no specific range for this measure.
Both MTC and traditional meta-analysis require stud-
ies to be sufficiently similar in order to pool their results.
To further investigate heterogeneity, where warranted,
subgroup analyses and meta-regressions [22, 28] were
considered. One subgroup analysis we planned was the
comparison of estimates before and after 2004 considering
potential change in management after the publication of
the Contreras et al. [29] study in the New England Journal
of Medicine. We considered other subgroup analyses by
age, gender, race, and prior immunosuppressive therapy
for lupus nephritis prior to the current episode, if data
were available.
Graphical aids, in the form of network diagrams, were
considered for NMA. We compared the NMA results
to pair-wise meta-analyses where possible. We per-
formed sensitivity analyses by using OR versus Peto’s
OR for estimation. The Grading of Recommendations
Assessment, Development and Evaluation (GRADE) ap-
proach was used to assess the quality of direct evidence
from meta-analysis versus estimates from the NMA,
assessing indirectness, imprecision, inconsistency, risk
of bias, publication bias, and other factors [30].
Several sensitivity analyses were conducted to test the
robustness of main NMA findings, including (1) random
versus fixed effects model, (2) the use of sepsis versus
serious infection data from Appel et al. [31], (3) the ex-
clusion of data from two observational studies previously
included in the 2012 Cochrane review versus inclusion
of all studies, and (4) comparing other medications to
CYC and CYC high dose as a group versus separately. We
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conducted sensitivity analyses based on different priors
[32] and compared the parameter estimates (i.e., OR (95 %
CrI)) and model fit criteria such as DIC and residual
deviance with these priors to the main analysis.
Results
Study cohort characteristics
A total of 32 RCTs with 2611 patients met inclusion cri-
teria and provided data for serious infections (Fig. 1).
Detailed study characteristics are provided in Additional
file 1: Appendix 2. Six studies examined induction and
maintenance phase treatments (19 %), four maintenance
phase treatments (13 %), and the rest induction phase
treatments (68 %) only. Nine were open-label RCTs and
two were quasi-RCTs. Study sample size ranged from 15
to 370. Most studies included patients with diffuse
glomerulonephritis and/or membranous glomerulo-
nephritis (Additional file 1: Appendix 2). Studies were
mostly single site studies except for nine studies (28 %)
that were multicenter. The majority of the patients in
the included studies were female. The risk of bias was
low for most criteria and unclear for some criteria
(Additional file 1: Appendix 3).
The network for serious infections contained multiple
treatments as well as sequential and combination regi-
mens (Fig. 2). As expected, most studies compared MMF
and high-dose CYC. The network had several direct com-
parisons of various medications and regimens to each
other. These studies included 2611 patients who had 332
serious infections (Additional file 1: Appendix 4). Of these
studies, 26 were two-arm, five three-arm, and one four-
arm, and these studies included 14 different treatments
(Table 1). Six out of 32 studies had at least one arm with
zero events. None of the included studies had all arms
with zero events (Additional file 1: Appendix 4). The
number of serious infections for each of the comparisons
(numerator) and the total number of patients available
(denominator) is shown in Additional file 1: Appendix 5.
For example, for the comparison of glucocorticoids and
CYC, 48 serious infections in 335 patients were available
and for low- and high-dose, 53 serious infections in 252
patients were available (Additional file 1: Appendix 5).
Comparison of immunosuppressive drugs with
glucocorticoids
Eleven studies provided data for these comparisons. Crude
rates of serious infections with immunosuppressive drugs
and glucocorticoids showed the highest crude serious in-
fection rate with high-dose glucocorticoids at 26.7 % (one
study only); rates were 15.1 % and 11.6 % with CYC and
MMF, respectively (Table 1). Crude rates for serious infec-
tions with other treatments are shown in Table 1.
We found that tacrolimus was associated with signifi-
cantly lower risk of serious infections compared to
standard-dose corticosteroid, with an OR of 0.33 (95 %
CrI, 0.12–0.88) (Table 2). We also found that MMF-AZA
(MMF followed by AZA) was associated with signifi-
cantly lower risk of serious infections as compared to
high-dose glucocorticoids, with a relative risk of 0.03
(95 % CrI, 0.00–0.56) (Table 2). Other differences com-
paring immunosuppressive drugs to glucocorticoids or
high-dose glucocorticoids did not reach statistical sig-
nificance (Fig. 3).
Comparison of immunosuppressive drugs with each other
Twenty-three studies provided data for these compari-
sons (three studies provided data for both compari-
sons). Crude rates of serious infections are shown in
Table 1, ranging 8.7 % for TAC to 20.6 % with CYC-
AZA, for treatments with more than one study. TAC
was associated with significantly lower risk of serious
infections compared to CYC, MMF, and AZA, with
ORs of 0.37, 0.40, and 0.32, respectively (Table 2). We
also found that MMF-AZA (MMF followed by AZA)
was associated with significantly lower odds of serious
infections as compared to low-dose CYC, high-dose
CYC, and CYC-AZA with ORs of 0.09, 0.07, and 0.14,
respectively (Table 2).
The staircase diagrams show the ORs for the compari-
sons of treatments where at least one comparison was
significant (Fig. 3). With the exception of the differences
discussed in the two sections above, other differences
did not reach statistical significance (Fig. 3). In order to
check the consistency of the NMA results, we conducted
the inconsistency analysis and compared with our con-
sistent NMA results (Fig. 4). Based on this comparison
between two models, only three points had a higher than
expected posterior mean difference (Fig. 4). Most param-
eter estimates are very similar between two models. For
Fig. 1 PRISMA flow chart for study selection. A total of 32 studies
provided data on serious infections
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the overall NMA, the tau (reciprocal of variance
between-study; a measure of heterogeneity) was 26.39,
and the standard deviation was 0.1949, which is less than
0.5, indicating that heterogeneity is low. We noted some
inconsistency of parameter estimates; however, sensitiv-
ity analysis that evaluated the results with and without
those studies showed that parameter estimates (effects
estimates, standard error, etc.) are mostly similar and
showed no change on interpretation of the results and
conclusions.
Comparison of NMA results to direct estimates from
meta-analyses for main findings
We compared the results from our NMA to traditional
pair-wise meta-analyses, where this was possible, TAC ver-
sus MMF and TAC versus CYC. The robustness of esti-
mates was indicated by minimal/no differences in
estimates between the NMA and the meta-analyses (TAC
vs. MMF, 0.40 vs. 0.42; and TAC vs. CYC, 0.37 vs. 0.28, re-
spectively; Additional file 1: Appendix 6). Heterogeneity,
as measured by I-squared, was 0 % for TAC versus MMF
and 0 % for TAC versus CYC for direct comparisons by
meta-analyses. The GRADE quality of evidence was mod-
erate for direct comparison with meta-analyses and mod-
erate for NMA estimates, downgraded for imprecision in
both cases.
Sensitivity analyses
We undertook multiple sensitivity analyses to test the
robustness of our study findings. Sensitivity analyses by
using the random effects versus fixed effects models
(Table 3) or by the type of method used for estimation
(OR vs. Peto’s OR) (Fig. 5) revealed no change in inter-
pretation and minimal change in estimates.
Replacing sepsis events (included in serious infection
definition) by serious infections in the Appel et al. [31]
study revealed slight differences in the significance of
MMF-AZA versus low-dose CYC, high-dose glucocorti-
coids, and high-dose CYC comparisons, i.e., these differ-
ences were no longer statistically significant; other
Fig. 2 Each node indicates a treatment included in the analysis. The lines represent the direct (head-to-head) comparisons identified in the literature.
The surface area of the nodes (represented as circles) represents the number of patients who received the treatment – the larger the size of the circle,
the greater the number of patients who received that treatment. For example, there were more patients treated with mycophenolate mofetil or
cyclophosphamide (left side of the figure) than tacrolimus or cyclosporine (right side of the figure). Some treatments are noted outside the nodes
simply due to longer names that would not fit within the circle size, proportional to the number of patients that received that treatment
Singh et al. BMC Medicine  (2016) 14:137 Page 5 of 12
Table 2 Serious infection risk in patients with lupus nephritis with various immunosuppressive drugs or corticosteroids showing
only the statistically significant results
Treatment Reference OR (95 % CrI) RR (95 % CrI) RD (95 % Crl)
TAC Glucocorticoids 0.33 (0.12–0.88) 0.36 (0.14–0.90) –0.09 (–0.15 to –0.01)
TAC CYC 0.37 (0.15–0.87) 0.41 (0.17–0.88) –0.07 (–0.14 to –0.01)
TAC MMF 0.40 (0.18–0.81) 0.43 (0.21–0.83) –0.07 (–0.14 to –0.02)
TAC AZA 0.32 (0.12–0.81) 0.35 (0.14–0.83) –0.09 (–0.20 to –0.02)
CYC LD TAC 4.84 (1.48–17.64) 4.00 (1.43–11.47) 0.15 (0.03 to 0.40)
HD glucocorticoids TAC 12.83 (1.53–119.90) 7.67 (1.47–25.14) 0.35 (0.03 to 0.79)
CYC HD TAC 6.60 (2.25–20.50) 5.06 (2.03–12.89) 0.20 (0.07 to 0.43)
MMF-AZA CYC LD 0.09 (0.01–0.76) 0.11 (0.01–0.79) –0.17 (–0.43 to –0.03)
MMF-AZA HD glucocorticoids 0.03 (0.00–0.56) 0.06 (0.00–0.61) –0.37 (–0.82 to –0.04)
MMF-AZA CYC HD 0.07 (0.01–0.54) 0.09 (0.01–0.60) –0.22 (–0.46 to –0.06)
MMF-AZA CYC-AZA 0.14 (0.02–0.71) 0.16 (0.02–0.75) –0.11 (–0.29 to –0.02)
All odds ratios are statistically significant
High-dose (HD) glucocorticoids were defined as one of the following or a similar regimen: (1) prednisone or methylprednisolone 1 gm/m2 qd intravenous × 3 at
entry, then one dose intravenous q month for 1 year; (2) prednisone 1 mg/kg po qd with a slow taper up to 1 year or longer taper (or unspecified taper in an
occasional case)
Glucocorticoids were defined as one of the following or a similar regimen: (1) prednisone 40 mg po qod for 8 weeks then taper to 10 mg qd within a year; (2)
60 mg qd for 1–3 months reduced to 20 mg/d by 6 months
CYC, low dose (LD): CYC IV 500 mg q 14 d × 6 doses or a similar regimen
CYC: CYC IV 0.5–1.0 gm/m2 q 2 month for 1 year or CYC PO 1–4 mg/kg daily for 4 years (standard dose) or a similar regimen
CYC, HD: CYC IV 0.5–1.0 gm/m2 q month × 6–9 months, then q3 months for 0.5–4 years or CYC PO 10 mg/kg daily or a similar regimen
MMF-AZA: MMF followed by AZA
CYC-AZA: CYC followed by AZA
CYC cyclophosphamide, MMF mycophenolate mofetil, AZA azathioprine, TAC tacrolimus, HD high dose, LD low dose
Table 1 Crude rates of serious infections with immunosuppressive drugs or corticosteroids in patients with lupus nephritis
Treatment #Studies # Events # Patients Aggregate rate, per patient Minimum rate Maximum rate
Glucocorticoids 10 30 179 0.181 0.106 0.291
CYC 12 46 285 0.151 0.092 0.240
MMF 12 69 728 0.116 0.072 0.182
AZA 8 45 266 0.184 0.095 0.329
TAC 5 14 171 0.087 0.052 0.141
CSA 3 10 65 0.166 0.091 0.283
CYC LD 4 21 128 0.172 0.114 0.252
HD glucocorticoids 1 4 15 0.267 0.104 0.533
CYC HD 9 60 506 0.131 0.073 0.225
AZA HD 1 2 20 0.100 0.00 1.131
LEF HD 1 3 70 0.043 0.00 0.090
CYC-AZA 3 15 74 0.206 0.118 0.333
MMF-AZA 1 2 32 0.063 0.00 0.146
RTX +MMF 1 12 72 0.167 0.081 0.253
CYC-AZA, CYC followed by AZA
MMF-AZA, MMF followed by AZA
RTX +MMF, RTX combined with MMF
CYC cyclophosphamide, MMF mycophenolate mofetil, AZA azathioprine, TAC tacrolimus, CSA cyclosporine, LEF leflunomide, HD high dose, LD low dose; when not
specified, standard dose should be inferred
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comparisons did not change in estimates or significance
(Additional file 1: Appendix 7). When we further excluded
two studies with observational data [33, 34] from the data-
set with serious infection data from Appel et al. [31], we
noted no change in estimates or significance except that
CYC-AZA versus TAC now became significant, 3.37
(0.75–15.56) versus 14.13 (1.07–220.2), although the confi-
dence intervals were wide (Additional file 1: Appendix 8).
When we combined CYC and high-dose CYC, most
associations did not change, except that one MMF-AZA
comparison became significant in the combined analyses
compared to previously: versus CYC (0.11 (0.01–0.91);
Additional file 1: Appendix 9).
Sensitivity analyses based on different priors were per-
formed. The parameter estimates were consistent with
these different priors to the main analysis (Additional
file 1: Appendix 10). The model fit criteria, such as DIC
and residual deviance, were also similar with those priors
(Additional file 1: Appendix 10).
Subgroup analysis
Comparison of studies before and after 2004 was per-
formed considering potential change in management
after the publication of the Contreras et al. [29] study
in the New England Journal of Medicine. For most
comparisons, the studies fell into one of the two pe-
riods, allowing no meaningful interpretation of results
for any time-period effect (Additional file 1: Appendix
11). Since we divided the studies into two time-periods,
the network was smaller and 95 % confidence intervals
wider and more imprecise with this subgroup analysis.
We could not perform subgroup analyses by age, gen-
der, race, and prior immunosuppressive therapy due to
lack of enough data presented by these characteristics
in the included studies.
Discussion
In our systematic review and network meta-ana-














































































Fig. 3 League tables highlight the main findings from the analysis. For each comparison, the random effects model odds ratios (OR) and 95 % credible
intervals are provided. The results of the plots are read from top to bottom and left to right. An OR < 1 means that the treatment in the top left is better
than the comparator treatment. For example, tacrolimus is better/safer than glucocorticoids (a) and mycophenolate mofetil-azathioprine is better/safer
than low-dose cyclophosphamide (b), since the odds of serious infections are lower in each case than the comparator. Significant results are in bold
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compared the risk of serious infections in patients with
lupus nephritis who were treated with immunosuppres-
sive drugs and/or glucocorticoids. We performed a
NMA that incorporated indirect and direct comparisons
and allowed us to compare several treatments to each
other. Importantly, for most of the comparisons, we also
had direct comparison trials. We performed several sen-
sitivity analyses and most of these confirmed the robust-
ness of the findings. Several study findings merit further
discussion.
We found that TAC was associated with lower risk of
serious infections compared to several other immunosup-
pressive drugs and to standard-dose glucocorticoids.
Specifically, compared to CYC, MMF, AZA, and standard-
dose glucocorticoids, TAC was associated with one-third
the odds of serious infections. High-dose CYC and high-
dose glucocorticoids were associated with 7–15 times
higher odds of serious infections compared to TAC, pro-
viding some evidence for dose-response, with odds going
from three-fold for standard dose to 7- to 15-fold for high
dose. These are new findings to our knowledge and were
robust in multiple sensitivity analyses. Sensitivity analyses
we performed, included the following: (1) random or fixed
effects model; (2) pair-wise meta-analyses versus NMA;
(3) OR versus Peto’s OR for estimation; (4) the use of
sepsis versus serious infection data from Appel et al. [31];
(5) exclusion of data from two observational studies
previously included in the 2012 Cochrane review versus
inclusion of all studies; and (6) comparing to CYC and
high-dose CYC in a combined treatment group versus the
treatments separately. Thus, the risk of serious infections
seems to be less with TAC compared to most comparable
immunosuppressive regimens. This finding is similar to
that of a large trial in nephrotic syndrome in children,
Table 3 Sensitivity analyses by random versus fixed effects for
serious infection risk by comparison of significant estimates
between random and fixed effects models
Comparison Random effects model Fixed effects model
Odds ratio (95 % CrI) Odds ratio (95 % CrI)
TAC vs. glucocorticoids 0.33 (0.12–0.88) 0.33 (0.13–0.82)
TAC vs. CYC 0.37 (0.15–0.87) 0.37 (0.16–0.82)
TAC vs. MMF 0.40 (0.18–0.81) 0.40 (0.20–0.78)
TAC vs. AZA 0.32 (0.12–0.81) 0.32 (0.13–0.77)
CYC LD vs. TAC 4.84 (1.48–17.64) 4.50 (1.43–14.50)
HD glucocorticoids vs. TAC 12.83 (1.53–119.90) 12.22 (1.58–105.70)
CYC HD vs. TAC 6.60 (2.25–20.50) 6.52 (2.38–18.95)
MMF-AZA vs. CYC LD 0.09 (0.01–0.76) 0.09 (0.01–0.74)
MMF-AZA vs. HD
glucocorticoids
0.03 (0.00–0.56) 0.21 (0.02–1.79)
MMF-AZA vs. CYC HD 0.07 (0.01–0.54) 0.07 (0.01–0.47)
MMF-AZA vs. CYC-AZA 0.14 (0.02–0.71) 0.14 (0.02–0.65)







All odds ratios are statistically significant
Odds ratios from either model are very similar to each other, denoting the
robustness of the analyses, regardless of assumptions
CYC cyclophosphamide, MMF mycophenolate mofetil, AZA azathioprine, TAC
tacrolimus, HD high dose, LD low dose; when not specified, standard dose
should be inferred
Fig. 4 The figure shows the deviances from consistency and the inconsistency models. Consistency model assumes that the evidence derived
from direct and indirect estimates should be in agreement. The inconsistency model does not make this assumption. Ideally, all deviances
should be 2 or below. There were 71 unconstrained data points. Three data points show deviances of > 2 (extreme right side in the figure).
Residual deviances from consistency versus inconsistency models were 72.49 versus 67.73 for 69 data points each. Deviance information
criteria was 325.65 versus 325.96, respectively, indicating that the inconsistency model is a slightly better fit for the data than the consistency
model. Thus, the model showed some evidence of inconsistency
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where 4/66 TAC- versus 16/65 CYC-treated patients had
serious infections [35]. In a recent systematic review and
meta-analysis of TAC for lupus nephritis, TAC (alone or
in combination with MMF) was more efficacious than
intravenous CYC and as efficacious as MMF for complete
or partial renal remission [36]. The review also reported
slight mortality advantage with TAC versus controls [36].
Our study finding of lower rate of serious infections, in
conjunction with superiority over a previously commonly
used therapy (intravenous CYC) might partially explain
mortality benefit with TAC.
We did not notice any systematic differences in study
populations or the stage of lupus nephritis between trials
of TAC versus other immunosuppressive medications.
Use of a lower start dose of TAC and titration to achieve
trough serum levels may have led to a smaller cumula-
tive TAC dose versus comparators. All included TAC
trials were of small sample size and performed in China
(non-Caucasian), not unlike several trials for other medi-
cations, which were performed internationally.
This information regarding the comparative risk of ser-
ious infections with various immunosuppressive drugs in
lupus nephritis can be helpful in conjunction with com-
parative efficacy data that can empower patients to expli-
citly weigh comparative risks and benefits. These data can
be effectively used for informed decision-making by pa-
tients with lupus nephritis, in general, but particularly in
patients with recurrent infections/serious infections or in
those with high-risk comorbidities that increase the risk of
serious infections. Compared to Whites, minorities have
higher incidence and prevalence of lupus nephritis [37, 38],
more severe disease and worse outcomes [39, 40], and
more than three times higher mortality [41, 42]. The rea-
sons for these worse outcomes in minorities are not clear,
but may be partially related to health access barriers, socio-
economic differences, and higher use of glucocorticoids
alone versus immunosuppressives plus glucocorticoids. Fu-
ture studies need to examine whether the risk difference in
serious infections with various medications varies by race/
ethnicity.
On the other, we found no significant differences between
MMF and CYC for serious infection risk, an important
study finding. The OR for serious infection with MMF
versus CYC was 0.98 (95 % CrI, 0.50–1.95) in our study,
which included 32 studies and was statistically not signifi-
cant. This is an area of great interest and debate since
MMF and CYC are among the most common immunosup-
pressive drugs used for the treatment of lupus nephritis. In
a meta-analysis published in 2007 that included five RCTs
with 307 patients [29], MMF was associated with a risk ra-
tio of 0.65 (96 % CI, 0.51–0.82; P < 0.001) of overall infec-
tions compared with CYC [9]. The most comprehensive
study to date, the 2012 Cochrane systematic review that in-
cluded six studies [31] with infection data for 683 patients
(total of 50 studies with 2846 patients included) [10],
showed that MMF was not associated with any increase in
the risk of major infections (defined as all-cause infections
other than herpes zoster) compared to intravenous CYC,
and the relative risk was 1.11 (95 % CI, 0.74–1.68) [10].
Our systematic review, meta-analysis, and NMA findings
support the earlier finding from the Cochrane systematic
review that a difference in the risk of serious infection risk
between CYC and MMF was not evident.
However, MMF-AZA was associated with lower odds of
serious infections compared to CYC-AZA, high-dose CYC,
low-dose CYC, and high-dose glucocorticoids, indicating
that some differences may exist between MMF and CYC
when followed by AZA. We need data from longer-term
studies or studies with a larger sample size. It also remains
to be seen whether the EURO-lupus CYC dose (low dose)
is a safer option than the regular CYC regimen, especially
with regards to the risk of serious infections. This is an
Fig. 5 Sensitivity analyses comparing method of estimation, odds ratio versus Peto’s odds ratio for meta-analyses of tacrolimus versus mycophenolate
mofetil and tacrolimus versus cyclophosphamide. Same analyses using the Peto Method for rare events
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important consideration for future studies of harms, since
CYC can be given in more than one dose, and most pre-
vious analyses have not accounted for CYC dose.
Another important aspect of serious infection risk is the
contribution of glucocorticoids to this risk, since they are
often used concomitantly with immunosuppressive drugs.
A previous meta-analysis of 25 RCTs showed that this risk
of major infection did not increase by combining immuno-
suppressive drugs with glucocorticoids for lupus nephritis
treatment, namely, the risk did not differ between CYC or
AZA plus glucocorticoids versus glucocorticoids alone [8].
On the other hand the renal-protective benefits of combin-
ing immunosuppressive drugs with glucocorticoids for in-
duction therapy have been clearly demonstrated decades
ago by an NIH study [43]. Studies that can carefully meas-
ure and control for corticosteroid use might help to delin-
eate the contributions they make to serious infection risk
when used concomitantly with immunosuppressive drugs.
Since our analyses include RCTs, among patients random-
ized to one of the immunosuppressive drugs, corticosteroid
use should be similar except when corticosteroid is used in
only one of the treatment arms. Rituximab is an emerging
treatment for lupus nephritis with some controversy re-
garding its efficacy. Our systematic review included only
one study with RTX versus placebo in patients receiving
MMF and glucocorticoids for lupus nephritis, and no dif-
ferences were noted in the risk of serious infections versus
other medications, including TAC. More data are needed
to define its role in the treatment of lupus nephritis.
Study strengths are the use of state-of-the-art systematic
review and NMA methodology, the use of large number
of trials (and patients) in the analyses, robustness of esti-
mates as demonstrated by no/minimal change in estimates
with sensitivity analyses, robustness with models using dif-
ferent priors, and the concordance of findings from NMA
with that from traditional pair-wise meta-analyses. The
overall quality of evidence for the main findings was mo-
derate, which must be considered while interpreting study
results.
Our study has several limitations. Study population
heterogeneity between included trials can lead to obser-
vations of differences between them, which may be at-
tributable to differences in the types of patients being
treated rather than the type of medication being used. In
our view, most RCTs were more similar than different,
since they enrolled patients with diffuse glomeruloneph-
ritis with very few focused on membranous nephropathy
and most RCTs were induction or induction/mainten-
ance. While some trials lasted several years, most were
6 months long and the number of patients was less than
100 for the majority of the trials. This leads to small
sample sizes and, in cases of rare events such as serious
infections, a small number of patients having the outcome.
This can lead to suboptimal power to detect all clinically
relevant differences between medications, i.e., type II error.
We may have missed some differences due to low power.
We performed a lot of comparisons, which could have also
led to observed significance of some differences just by
chance, i.e., type I error. We think this (type I error) is less
likely given the rarity of serious infection outcome and our
main concern is missing important differences due to the
low number of events (type II error). This means that fu-
ture NMAs in this area will greatly benefit from the
addition of new large studies. We limited the search to the
English language. Exclusion of studies in non-English lan-
guage and other databases may have led to missing some
pertinent studies. Publication bias assessment was planned
(funnel plot), but could not be done due to the lack of
treatment pairs with more than 10 studies.
Conclusions
In summary, we found that tacrolimus was associated
with a lower risk of serious infections compared to other
immunosuppressives or glucocorticoids. Similar observa-
tions were also noted for MMF-AZA. Our systematic re-
view and NMA provides a state-of-the-art analyses of
the risk of serious infections with immunosuppressives
and glucocorticoids. The overall quality of evidence was
moderate. This study provides data that can be used
during discussions with patients to better inform them
of the comparative risks with various treatment options
for lupus nephritis. The results of these analyses will be
used in developing a patient decision aid, which will be
tested in a randomized trial.
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